申请人:Hong Kong Baptist University
公开号:US20160243264A1
公开(公告)日:2016-08-25
The present invention is in the field of pharmaceuticals and chemical industries. In particular, one aspect of the present invention relates to methods for labeling, imaging and detecting the beta-amyloid (Aβ) peptides, oligomers, and fibrils in vitro and in vivo via magnetic resonance and florescence imaging by using modified carbazole-based fluorophores. A further aspect of the present invention relates to a method of reducing and preventing aggregation of beta-amyloid peptides for Alzheimer's disease (AD) as well as of treating and/or preventing Alzheimer's disease by using the modified carbazole-based fluorophore. The modified carbazole-based fluorophore according to an embodiment of the present invention is prepared by conjugating a carbazole-based fluorophore with magnetic nanoparticles to form a conjugate which is permeable to blood brain barrier of a subject being introduced therewith.
本发明涉及制药和化工行业。具体而言,本发明的一个方面涉及使用改良的基于咔唑的荧光物质通过磁共振和荧光成像在体内和体外标记、成像和检测β-淀粉样蛋白(Aβ)肽、寡聚体和纤维的方法。本发明的另一个方面涉及一种减少和预防β-淀粉样蛋白在阿尔茨海默病(AD)中聚集的方法,以及使用改良的基于咔唑的荧光物质治疗和/或预防阿尔茨海默病的方法。根据本发明实施例的改良基于咔唑的荧光物质是通过将基于咔唑的荧光物质与磁性纳米颗粒偶联而制备的,形成的共轭物质能够穿透引入的受试者的血脑屏障。